Webster and MedEquity Acquire Belmar Pharmacies to Expand Access to Personalized Compounded Medications

Recently, VCBeat (WeChat Official Account: vcbeat) learned that Webster Equity Partners and MedEquity Capital have announced the acquisition of Belmar Pharmacies, based in Colorado. No financial terms of the transaction were disclosed at this time.

Belmar Pharmacies, established in 1985 and headquartered in Golden, Colorado, is a specialty pharmacy platform dedicated to the management and compounding of bioidentical hormone replacement therapy (BHRT) and other hormone-related health products. Belmar strictly adheres to Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, serving approximately 64,000 patients through around 6,500 compounded prescriptions annually across 46 U.S. states.

Belmar’s mission is to provide patients with personalized compounded medications and a superior customer experience at reasonable prices. The pharmacy improves patient treatment outcomes through effective communication among patients, pharmacists, and physicians, as well as by delivering high-quality traditional compounded medications. Belmar distinguishes itself from other pharmacies in the United States through its unique bioidentical hormone replacement therapy (BHRT) oral tablets, which utilize a proprietary base free of parabens and petroleum. Offering a wide range of dosage forms—including sublingual tablets, pH-balanced vaginal tablets, capsules, topical gels, suppositories, vaginal creams, and pellet implants—the pharmacy is recognized within the industry as an expert in dosage form formulation.

Belmar’s compounded medications adhere to USP <795> guidelines, and all active pharmaceutical ingredients are accompanied by certificates of analysis. Furthermore, the company tests for common contaminants, including heavy metals such as arsenic, lead, and mercury, as well as bacteria such as Escherichia coli and Salmonella.

David Malm, Executive Partner at Webster Equity Partners, stated, “We are delighted to collaborate with Belmar and its team to support the company’s growth and deliver high-quality services to customers. We will expand Belmar’s market reach and continue to serve a broader population.”

Dave Hill, CEO of Belmar, stated, “We chose to partner with Webster and MedEquity because they are highly optimistic about Belmar’s future growth. The teams at Webster and MedEquity have brought the necessary capital and expertise to Belmar, and we believe that Belmar will become an industry leader.”

Webster Equity Partners, founded in 2003, is a private equity firm focused on investing in the branded consumer and healthcare services sectors. The company provides equity financing to corporate management teams. Webster manages over $600 million in assets.

MedEquity Capital is a healthcare private equity firm focused on investing in the healthcare services sector. Since its inception, MedEquity has invested hundreds of millions in more than 20 companies, achieving equity returns of up to 10%.

(Compiled by Song Chenchen)